Abstract
The risk of plague as a bioweapon has prompted increasing research efforts to develop plague vaccines due to its extreme virulence and the ease of its transmission. Subunit vaccines that contain F1 and LcrV antigens of Y. pestis have been tested for safety and immunogenicity, but doubts have been raised about whether subunit vaccines that engender antibody responses will protect against pneumonic plague, which requires both humeral and cellular immune responses for protection. The live, attenuated vaccine EV76, a pgm locus deficient Y. pestis strain, has been used for a long time in the Former Soviet Union and some Asian countries, but is not commercially available in the US and Europe due to safety concerns. However, the live attenuated Y. pestis vaccines are still considered to be the most effective way to prevent plague. In this review, we present our opinions about rationally creating live, safe and immunogenic Y. pestis vaccines with potential use for human based on established researches.
Keywords: Immune response, Live attenuated Y. pestis vaccines, Plague, Yersinia pestis.
Current Pharmaceutical Biotechnology
Title:Rational Considerations about Development of Live Attenuated Yersinia pestis Vaccines
Volume: 14 Issue: 10
Author(s): Wei Sun and Roy Curtiss
Affiliation:
Keywords: Immune response, Live attenuated Y. pestis vaccines, Plague, Yersinia pestis.
Abstract: The risk of plague as a bioweapon has prompted increasing research efforts to develop plague vaccines due to its extreme virulence and the ease of its transmission. Subunit vaccines that contain F1 and LcrV antigens of Y. pestis have been tested for safety and immunogenicity, but doubts have been raised about whether subunit vaccines that engender antibody responses will protect against pneumonic plague, which requires both humeral and cellular immune responses for protection. The live, attenuated vaccine EV76, a pgm locus deficient Y. pestis strain, has been used for a long time in the Former Soviet Union and some Asian countries, but is not commercially available in the US and Europe due to safety concerns. However, the live attenuated Y. pestis vaccines are still considered to be the most effective way to prevent plague. In this review, we present our opinions about rationally creating live, safe and immunogenic Y. pestis vaccines with potential use for human based on established researches.
Export Options
About this article
Cite this article as:
Sun Wei and Curtiss Roy, Rational Considerations about Development of Live Attenuated Yersinia pestis Vaccines, Current Pharmaceutical Biotechnology 2013; 14 (10) . https://dx.doi.org/10.2174/1389201014666131226122243
DOI https://dx.doi.org/10.2174/1389201014666131226122243 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Treatment of Refractory Autoimmune Diseases with Ablative Immunotherapy Using Monoclonal Antibodies and / or High Dose Chemotherapy with Hematopoietic Stem Cell Support
Current Pharmaceutical Design The Role of Selenium in Oxidative Stress and in Nonthyroidal Illness Syndrome (NTIS): An Overview
Current Medicinal Chemistry Therapies Targeting Inflammation After Stent Implantation
Current Vascular Pharmacology Intravenous and Regional Paclitaxel Formulations
Current Medicinal Chemistry Adenovirus/PSA (Ad5-PSA) Vaccination for Prostate Cancer: Pre-Clinical and Clinical Development
Current Cancer Therapy Reviews Calcitonin Gene-Related Family Peptides in Vascular Adaptations, Uteroplacental Circulation, and Fetal Growth
Current Vascular Pharmacology Dysregulated Interleukin -33/ST2 Pathway Perpetuates Chronic Inflammation in Hashimoto’s Thyroiditis
Endocrine, Metabolic & Immune Disorders - Drug Targets Chemokines and Their Receptors: Potential Therapeutic Targets for Bone Cancer Pain
Current Pharmaceutical Design Posttranslational Modifications and Subcellular Localization Signals: Indicators of Sequence Regions without Inherent 3D Structure?
Current Protein & Peptide Science Neuroinflamm-Aging and Neurodegenerative Diseases: An Overview
CNS & Neurological Disorders - Drug Targets Recent Patents in Antiviral siRNAs
Recent Patents on Anti-Infective Drug Discovery Efficacy of Lopinavir/Ritonavir Compared With Standard Care for Treatment of Coronavirus Disease 2019 (COVID-19): A Systematic Review
Infectious Disorders - Drug Targets Biocompatibility and Biotolerability Assessment of Microspheres Using a Whole Blood Model
Micro and Nanosystems An Overall Picture of Chemokine Receptors: Basic Research and Drug Development
Current Pharmaceutical Design Novel Insights into Biased Agonism at G Protein-Coupled Receptors and their Potential for Drug Design
Current Pharmaceutical Design Synergism Effects of Ursolic Acid Supplementation on the Levels of Irisin, C-reactive Protein, IL-6, and TNF-α During High-intensity Resistance Training in Low Activity Men
Cardiovascular & Hematological Disorders-Drug Targets Transcatheter Embolization Therapy in Liver Cancer
Recent Patents on Medical Imaging Antiviral Drugs that Target Cellular Proteins May Play Major Roles in Combating HIV Resistance
Current Pharmaceutical Design Effects of Biologic Agents and Other Disease-Modifying Antirheumatic Drugs on Cardiovascular Outcomes in Psoriasis and Psoriatic Arthritis: A Systematic Review
Current Pharmaceutical Design Treatment of Hepatitis C Cirrhotic Patients With Directly Acting Antivirals: A Multicenter Study
Infectious Disorders - Drug Targets